137 related articles for article (PubMed ID: 3517190)
1. Type-specific monoclonal antibody enhances the local phagocytic response to group B streptococcal infection.
Shigeoka AO; Weber ME; Pincus SH; Pritchard DG; Egan ML; Hill HR
J Infect Dis; 1986 Jun; 153(6):1170-3. PubMed ID: 3517190
[No Abstract] [Full Text] [Related]
2. Monoclonal antibody preparations for immunotherapy of experimental GBS infection.
Shigeoka AO; Pincus SH; Rote NS; Pritchard DG; Santos JI; Hill HR
Antibiot Chemother (1971); 1985; 35():254-66. PubMed ID: 3901902
[No Abstract] [Full Text] [Related]
3. Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against group B streptococci.
Hill HR; Shigeoka AO; Augustine NH; Pritchard D; Lundblad JL; Schwartz RS
J Exp Med; 1984 Jun; 159(6):1618-28. PubMed ID: 6374010
[TBL] [Abstract][Full Text] [Related]
4. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci.
Shigeoka AO; Jensen CL; Pincus SH; Hill HR
J Infect Dis; 1984 Jul; 150(1):63-70. PubMed ID: 6379061
[TBL] [Abstract][Full Text] [Related]
5. The loss of opsonic activity of bovine milk whey following depletion of IgA.
Mackie DP; Meneely DJ; Pollock DA; Logan EF
Vet Immunol Immunopathol; 1986 Feb; 11(2):193-8. PubMed ID: 3515746
[TBL] [Abstract][Full Text] [Related]
6. Effect of fibronectin on IgA-mediated uptake of type III group B streptococci by phagocytes.
Yang KD; Bohnsack JF; Hawley MM; Augustine NH; Knape WA; Egan ML; Pritchard DG; Hill HR
J Infect Dis; 1990 Feb; 161(2):236-41. PubMed ID: 2405069
[TBL] [Abstract][Full Text] [Related]
7. Murine type-specific monoclonal antibodies in experimental group B streptococcal infection: interaction with complement components and phagocytes.
Shigeoka AO
Semin Perinatol; 1990 Aug; 14(4 Suppl 1):30-9. PubMed ID: 2237468
[No Abstract] [Full Text] [Related]
8. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1.
Raff HV; Bradley C; Brady W; Donaldson K; Lipsich L; Maloney G; Shuford W; Walls M; Ward P; Wolff E
J Infect Dis; 1991 Feb; 163(2):346-54. PubMed ID: 1988519
[TBL] [Abstract][Full Text] [Related]
9. The opsonic activity of whey and sera from heifers experimentally infected with Streptococcus agalactiae.
Mackie DP; Pollock DA; Logan EF
Br Vet J; 1985; 141(4):349-54. PubMed ID: 3896387
[No Abstract] [Full Text] [Related]
10. Evaluation of group B streptococcal opsonins by radiolabeled bacterial uptake.
Allred CD; Shigeoka AO; Hill HR
J Immunol Methods; 1979; 26(4):355-63. PubMed ID: 379227
[No Abstract] [Full Text] [Related]
11. Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus.
Kim KS; Wass CA; Kang JH; Anthony BF
J Infect Dis; 1986 Jun; 153(6):1092-7. PubMed ID: 3517187
[TBL] [Abstract][Full Text] [Related]
12. Macrophages and resistance of newborn rats to infection.
Schuit KE
J Reticuloendothel Soc; 1981 Nov; 30(5):341-6. PubMed ID: 7033529
[No Abstract] [Full Text] [Related]
13. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
Kasper DL; Paoletti LC; Wessels MR; Guttormsen HK; Carey VJ; Jennings HJ; Baker CJ
J Clin Invest; 1996 Nov; 98(10):2308-14. PubMed ID: 8941648
[TBL] [Abstract][Full Text] [Related]
14. Immunoprecipitation and opsonic cross-reaction between type-14 pneumococcus and group-B streptococcus type III.
Fischer GW; Lowell GH; Crumrine MH; Wilson SR
Lancet; 1979 Jan; 1(8107):75-7. PubMed ID: 84130
[TBL] [Abstract][Full Text] [Related]
15. Cellular and humoral aspects of host defense mechanisms against GBS.
Gotoff SP; Boyer KM
Antibiot Chemother (1971); 1985; 35():142-56. PubMed ID: 3901891
[No Abstract] [Full Text] [Related]
16. Luminol-enhanced chemiluminescence for evaluation of type III group B streptococcal opsonins in human sera.
Anderson DC; Edwards MS; Baker CJ
J Infect Dis; 1980 Mar; 141(3):370-81. PubMed ID: 6988524
[TBL] [Abstract][Full Text] [Related]
17. IgG subclasses and neonatal infections with group B streptococci.
Christensen KK; Christensen P
Monogr Allergy; 1988; 23():138-47. PubMed ID: 2455218
[No Abstract] [Full Text] [Related]
18. Pooled human IgG hyperimmune for type III group B streptococci: evaluation against multiple strains in vitro and in experimental disease.
Givner LB; Baker CJ
J Infect Dis; 1991 May; 163(5):1141-5. PubMed ID: 2019763
[TBL] [Abstract][Full Text] [Related]
19. Demonstration of opsonic activity and in vivo protection against group B streptococci type III by Streptococcus pneumoniae type 14 antisera.
Fischer GW; Lowell GH; Crumrine MH; Bass JW
J Exp Med; 1978 Sep; 148(3):776-86. PubMed ID: 29937
[TBL] [Abstract][Full Text] [Related]
20. A polyclonal human IgG preparation hyperimmune for type III, group B Streptococcus: in vitro opsonophagocytic activity and efficacy in experimental models.
Givner LB; Edwards MS; Baker CJ
J Infect Dis; 1988 Oct; 158(4):724-30. PubMed ID: 3049837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
